Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-08-12 DOI:10.1002/hon.3299

Carmen Martínez, Esther Carcelero, Antonio Gutiérrez, Esther Sancho, Josep Maria Martí-Tutusaus, Laura Magnano, Pablo Mozas, Francesc Fernández-Avilés, María Gabriela Antelo, Xavier Setoain, Sonia Rodríguez, Jordi Esteve

引用次数: 0

Abstract

Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.

查看原文本刊更多论文

使用布伦妥昔单抗-AVD对ABVD后正电子发射断层扫描呈阳性的晚期霍奇金淋巴瘤患者进行升级治疗的疗效。

接受ABVD治疗的晚期霍奇金淋巴瘤患者如果中期FDG-PET（iPET）呈阳性，预后较差。研究表明，升级至BEACOPP可改善无进展生存期（PFS）。然而，目前还缺乏随机试验来确定最佳的强化策略。我们报告了15例iPET阳性患者接受A-AVD治疗后的A-AVD升级治疗结果。总反应率和完全反应率分别为 80% 和 60%。四名患者接受了挽救治疗，随后进行了自体干细胞移植。在中位17个月的随访中，所有患者均存活，87%完全缓解，1年PFS为57.8%。对于因年龄、合并症或偏好而不符合BEACOPP条件的患者，A-AVD升级疗法可能是一个可行的替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.